Los Pinos Elisabet De Sells 15,955 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.93 on Thursday. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The stock’s 50-day moving average is $8.50 and its two-hundred day moving average is $8.92. The firm has a market cap of $396.10 million, a P/E ratio of -4.58 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional Investors Weigh In On Aura Biosciences

A number of large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after acquiring an additional 3,612 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares during the last quarter. Renaissance Technologies LLC boosted its position in Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares during the period. American Century Companies Inc. acquired a new position in Aura Biosciences during the second quarter valued at approximately $119,000. Finally, Rhumbline Advisers raised its position in shares of Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the period. 96.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on AURA. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Scotiabank lifted their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.